Philip Morris International (PM)
NYSEConsumer StaplesTobaccoSnapshot 2026-09-14
$194.86+1.99%
Close 2026-09-14 · 1-day change
NYSEConsumer StaplesTobaccoSnapshot 2026-09-14
Research Workspace
Put PM beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Staples is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Adjusted diluted EPS growth excluding currency: FY26 EPS growth ~+1.4% vs 9% target.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskPM's growth in smoke-free products must continue to justify its current price. Revenue grew 10% year over year, and the last quarter beat expectations. It trades at 24× P/E versus a 16× peer median, indicating the market reflects less growth than we forecast. The primary risk is the adjusted diluted EPS growth, which is only about 1.4% against a 9% target. Peer multiples imply a price about 5% below where it trades. This read is provisional; the thesis is on watch due to pressure on a primary pillar.
Trailing returns as of 2026-09-14. PM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering PM (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for PM in the last 4 months.
Continue this research
Compare PM with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PM Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Tobacco — fair value, gap to price, and forward P/E.
Compare the value case
Put PM next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Invest in and grow smoke-free products
Expansion of smoke-free products aligns with growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $194.86
The last 12 months of price, then the range of analyst 12-month targets from today’s $194.86.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Invest in and grow smoke-free products
Strong growth in smoke-free products supports management's objectives.
Advances: Invest in and grow smoke-free products
Confirms ongoing commitment to smoke-free products.
Advances: Increase adjusted diluted EPS by 9% to 11% excluding currency
Hiking profit guidance aligns with EPS growth target.
Advances: Invest in and grow smoke-free products
FDA authorization enhances ZYN's market potential.
Collaboration with Altria strengthens manufacturing capabilities.
Advances: Invest in and grow smoke-free products
Contract manufacturing deals support growth in smoke-free products.
New ZYN clearance supports smoke-free product growth.
